Want to see CVKD full AI Analyst Report?
CVKD Stock Chart & Stats
$5.22
-$1.27(-7.12%)
At close: 4:00 PM EST
$5.22
-$1.27(-7.12%)
Day’s Range― - ―
52-Week Range$2.55 - $14.64
Previous CloseN/A
Volume16.20K
Average Volume (3M)57.36K
Market Cap
$8.75M
Enterprise Value$6.58M
Total Cash (Recent Filing)$2.31M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta1.18
Next Earnings
Aug 06, 2026EPS Estimate
-1.55Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-5.63
Shares Outstanding2,868,247
10 Day Avg. Volume57,981
30 Day Avg. Volume57,363
Financial Highlights & Ratios
PEG Ratio0.04
Price to Book (P/B)4.94
Price to Sales (P/S)0.00
P/FCF Ratio-1.07
Enterprise Value/Market Cap0.75
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-6.89K
Enterprise Value/Ebitda-0.55
Forecast
1Y Price Target
$29.00Price Target Upside455.56% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)-5.52
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Phase 3 FDA Guidance For CAD-1005FDA End-of-Phase 2 guidance materially reduces regulatory uncertainty for CAD-1005 by setting trial design, endpoints and safety expectations. Clear pivotal trial parameters support a direct Phase 3 path and strengthen the likelihood of a coherent registration program toward a potential 2029 U.S. marketing application.
Pursuit Of Rare Pediatric Disease DesignationSeeking Rare Pediatric Disease Designation for tecarfarin targets an underserved orphan population and can enable incentives like priority review pathways or voucher opportunities. This bolsters commercial and partnership appeal, allows streamlined trial designs, and creates durable strategic optionality in niche markets.
Low Leverage / No DebtZero reported debt provides financial flexibility and lowers default risk while developing clinical assets. Low leverage allows management to prioritize R&D and structure equity or warrant financings without fixed interest burdens, preserving operating cash for trials and strategic partnerships over the medium term.
Bears Say
Pre-revenue With High Cash BurnSustained negative operating and free cash flow (~-$11M TTM) while pre-revenue means the company relies on external financing to fund development. Persistent burn erodes runway, forces frequent capital raises, and imposes long-term pressure on program completion unless substantial non-dilutive funding or partnerships are secured.
Shrinking Equity BaseRapid decline in shareholders' equity signals cumulative losses and weak capital cushion. A diminished equity base reduces financial resilience, limits leverage for non-dilutive financing, and increases the probability and potential size of future dilutive issuances to sustain clinical programs and operations.
Warrant-based Financing And Dilution OverhangWarrant inducement deals provide near-term cash but create multi-year dilution and issuance complexity via new warrants and placement agent rights. This financing structure can depress long-term per-share economics, complicate future capital raises, and create persistent overhang that affects partner negotiations and shareholder returns.
Cadrenal Therapeutics, Inc. News
CVKD FAQ
What was Cadrenal Therapeutics, Inc.’s price range in the past 12 months?
Cadrenal Therapeutics, Inc. lowest stock price was $2.55 and its highest was $14.64 in the past 12 months.
What is Cadrenal Therapeutics, Inc.’s market cap?
Cadrenal Therapeutics, Inc.’s market cap is $8.75M.
When is Cadrenal Therapeutics, Inc.’s upcoming earnings report date?
Cadrenal Therapeutics, Inc.’s upcoming earnings report date is Aug 06, 2026 which is in 37 days.
How were Cadrenal Therapeutics, Inc.’s earnings last quarter?
Cadrenal Therapeutics, Inc. released its earnings results on May 07, 2026. The company reported -$1.04 earnings per share for the quarter, missing the consensus estimate of N/A by -$1.04.
Is Cadrenal Therapeutics, Inc. overvalued?
According to Wall Street analysts Cadrenal Therapeutics, Inc.’s price is currently Undervalued.
Does Cadrenal Therapeutics, Inc. pay dividends?
Cadrenal Therapeutics, Inc. does not currently pay dividends.
What is Cadrenal Therapeutics, Inc.’s EPS estimate?
Cadrenal Therapeutics, Inc.’s EPS estimate is -1.55.
How many shares outstanding does Cadrenal Therapeutics, Inc. have?
Cadrenal Therapeutics, Inc. has 2,868,247 shares outstanding.
What happened to Cadrenal Therapeutics, Inc.’s price movement after its last earnings report?
Cadrenal Therapeutics, Inc. reported an EPS of -$1.04 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -2.431%.
Which hedge fund is a major shareholder of Cadrenal Therapeutics, Inc.?
Currently, no hedge funds are holding shares in CVKD
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Cadrenal Therapeutics, Inc.
Cadrenal Therapeutics, Inc. operates as a biopharmaceutical enterprise primarily engaged in clinical development. The company's core focus is the advancement of Tecarfarin, a novel therapeutic agent that has received orphan drug designation. This treatment is engineered to prevent systemic thromboembolism originating from cardiac issues in patients suffering from both end-stage renal disease and atrial fibrillation. Established in 2022, the firm is headquartered in Ponte Vedra, Florida.
CVKD Stock 12 Month Forecast
Average Price Target
$29.00
▲(455.56% Upside)
Technical Analysis
Daré Bioscience
―
Vyome Holdings
―
Collplant Holdings
―
Lunai Bioworks
―
Tao Synergies
―
Ownership Overview
10.67% Insiders
2.05% Mutual Funds
0.06% Other Institutional Investors
85.26% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---